montelukast and Zika-Virus-Infection

montelukast has been researched along with Zika-Virus-Infection* in 1 studies

Other Studies

1 other study(ies) available for montelukast and Zika-Virus-Infection

ArticleYear
Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation.
    Biochemical and biophysical research communications, 2022, 05-28, Volume: 606

    Flavivirus, such as Dengue Virus (DENV) and Zika virus (ZIKV), infects millions of people and cause the death of thousands of people every year. Despite many efforts, there is no approved anti-flaviviral treatment available. In particular, some antiflavivirus compounds were investigated the cellular activities of DENV and ZIKV, but lacking the exploration of specific target enzyme, thereby resulting in the hindrance of structure-based drug design. One example is Montlukast, which was found to inhibit the replicon replication in DENV and ZIKV infected cells, with EC

    Topics: Acetates; Antiviral Agents; Cyclopropanes; Enzyme Inhibitors; Flavivirus; Humans; Peptide Hydrolases; Protease Inhibitors; Quinolines; Sulfides; Viral Nonstructural Proteins; Zika Virus; Zika Virus Infection

2022